DURHAM, N.C. — Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE). The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease...

Basel, Switzerland – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction,...

AUSTIN, Texas — AlphaRose Therapeutics, a pioneer in precision genetic medicine, announced it has been awarded National Institute of Health’s (NIH) Small Business Innovation Research (SBIR) Fast Track grant. This highly competitive funding will accelerate the clinical development of Rosiphersen (ART-001), the company’s lead antisense oligonucleotide (ASO) therapy designed to treat...